Form 4: Gain Therapeutics Director Acquires Stock Options
SEC Form 4 Filing
Director Claude Nicaise acquired 15,000 stock options in Gain Therapeutics, Inc. on June 24, 2024.
Summary
- Claude Nicaise, a director of Gain Therapeutics, Inc. (GANX), acquired 15,000 stock options on June 24, 2024.
- The exercise price of the stock options is $1.29.
- The options vest in 12 equal monthly installments starting July 24, 2024, contingent upon continuous service.
- The options expire on June 24, 2034.
Sentiment
Score: 5
Explanation: This is a neutral event. A director receiving stock options is a common practice and doesn't inherently indicate positive or negative sentiment.
Industry Context
This is a standard SEC Form 4 filing, indicating a change in beneficial ownership by a company insider. It's a routine part of corporate governance and provides transparency to the market.
Stakeholder Impact
- The acquisition of stock options by a director could be perceived positively by shareholders as it aligns the director's interests with the company's performance.
Key Dates
| Date | Description |
|---|---|
| 06/24/2024 | Date of transaction: Director acquired 15,000 stock options. |
| 07/24/2024 | Vesting start date: Options vest in 12 equal monthly installments commencing on this date. |
| 06/26/2024 | Date of report filing. |
| 06/24/2034 | Expiration date: Stock options expire on this date. |
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.